GlassScriptPhysician profile
Syed N Raza
NPI 1700827839
$23,091.89
in general payments reported to CMS, 2019-2025
82 companies · $7,787 in 2025
The $7,787 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,606 · 2020: $1,328 · 2021: $1,859 · 2022: $1,535 · 2023: $1,676 · 2024: $4,300 · 2025: $7,787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $1,629 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,981.28 |
| Long Term Medical Supply Or Device Loan | $1,629.42 |
| Education | $152.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,529.24 | 2019-2025 | |
| Kite Pharma, INC. | $1,833.02 | 2020-2025 | Yescarta |
| Incyte Corporation | $1,353.87 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Janssen Biotech, INC. | $1,151.67 | 2019-2025 | Erleada, Rybrevant, Akeega |
| Genentech USA, INC. | $1,120.51 | 2019-2025 | Polivy, Venclexta, Tecentriq |
| Astrazeneca Pharmaceuticals LP | $1,110.18 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $1,014.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,010.91 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $888.65 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Pfizer INC. | $713.78 | 2019-2025 | |
| US Oncology Corporate, INC. | $682.56 | 2023-2025 | |
| Celgene Corporation | $645.19 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Daiichi Sankyo INC. | $501.90 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Amgen INC. | $489.53 | 2019-2023 | Kyprolis, Lumakras, Vectibix |
| Eisai INC. | $474.54 | 2019-2025 |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $466.40 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $458.22 | 2022-2025 | Fotivda |
| Lilly USA, LLC | $386.20 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $366.22 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Glaxosmithkline, LLC. | $356.68 | 2023-2025 | Ojjaara, Shingrix, Blenrep |
| Abbvie INC. | $262.33 | 2019-2025 | |
| Astellas Pharma US INC | $252.10 | 2019-2024 | Padcev |
| Puma Biotechnology, INC. | $243.33 | 2019-2025 | |
| Sobi, INC | $241.85 | 2023-2025 | |
| Adc Therapeutics America, INC. | $231.47 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $221.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $218.24 | 2019-2025 | Libtayo, Lynozyfic |
| Array Biopharma INC | $183.80 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmaessentia USA Corporation | $155.76 | 2025 | Besremi |
| Karyopharm Therapeutics INC. | $147.68 | 2020-2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $144.25 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Tersera Therapeutics LLC | $141.39 | 2019-2025 | Zoladex |
| Myriad Genetic Laboratories, INC. | $136.64 | 2023 | Precisetumor |
| Gilead Sciences, INC. | $135.40 | 2019-2025 | Trodelvy |
| Teva Pharmaceuticals USA, INC. | $123.31 | 2019-2020 | |
| Seagen INC. | $121.97 | 2019-2023 | Adcetris, Tukysa |
| Stemline Therapeutics INC. | $116.66 | 2024-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $115.36 | 2019-2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $113.59 | 2024-2025 | Monoferric, Cosela |
| Beigene USA, INC. | $107.25 | 2024-2025 | Brukinsa |
| Sumitomo Pharma America, INC. | $106.56 | 2023-2025 | Orgovyx |
| Taiho Oncology, INC. | $103.61 | 2019-2025 | |
| Exelixis INC. | $99.58 | 2019-2020 | |
| Geron Corporation | $88.34 | 2024-2025 | Rytelo |
| Spectrum Pharmaceuticals INC. | $79.48 | 2024-2025 | Rolvedon |
| Servier Pharmaceuticals LLC | $79.18 | 2024-2025 | |
| Springworks Therapeutics, INC. | $77.30 | 2024-2025 | Ogsiveo, Gomekli |
| Azurity Pharmaceuticals, INC. | $76.49 | 2024-2025 | Danziten, Vivimusta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.32 | 2019 | |
| Medtronic Vascular, INC. | $72.58 | 2020 | |
| Tempus Ai, INC | $71.40 | 2024-2025 | Xt Cdx |
| Ipsen Biopharmaceuticals, INC | $70.37 | 2023-2025 | Onivyde, Somatuline Depot |
| Amneal Pharmaceuticals LLC | $70.12 | 2023-2024 | Avastin, Neupogen, Neulasta |
| Deciphera Pharmaceuticals INC. | $69.03 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Foundation Medicine, INC. | $65.13 | 2020-2023 | Foundationone Cdx |
| Beone Medicines USA, INC. | $64.55 | 2025 | Brukinsa |
| Emd Serono, INC. | $63.09 | 2024-2025 | |
| Immunocore Limited | $58.67 | 2024-2025 | Kimmtrak |
| Verastem, INC. | $56.16 | 2019 | |
| Amag Pharmaceuticals, INC. | $53.55 | 2019 | |
| Legend Biotech USA INC. | $53.31 | 2025 | Carvykti |
| Sirtex Medical INC | $45.37 | 2024 | Sir-Spheres Microspheres |
| Pharmacyclics LLC, An Abbvie Company | $44.93 | 2019-2023 | Imbruvica |
| Shield Therapeutics INC | $44.79 | 2023-2025 | Accrufer |
| Clovis Oncology, INC. | $38.08 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $35.99 | 2025 | Enjaymo, Sylvant |
| Otsuka America Pharmaceutical, INC. | $32.32 | 2025 | Jynarque |
| Fresenius Kabi USA, LLC | $31.34 | 2025 | Stimufend |
| Blueprint Medicines Corporation | $30.92 | 2020-2024 | Ayvakit |
| Janssen Pharmaceuticals, INC | $30.43 | 2019-2020 | |
| Kyowa Kirin, INC. | $30.15 | 2019 | |
| Genmab U.S., INC. | $28.32 | 2024 | Epkinly |
| Adaptive Biotechnologies Corporation | $23.69 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $22.01 | 2019 | |
| Syndax Pharmaceuticals, INC. | $21.42 | 2025 | |
| Octapharma USA, INC. | $20.00 | 2024 | Panzyga |
| Biocon Biologics INC | $19.90 | 2024 | Fulphila |
| Acrotech Biopharma INC. | $15.50 | 2024 | Beleodaq |
| Agios Pharmaceuticals, INC. | $15.14 | 2024 | |
| Cti Biopharma Corp. | $15.10 | 2023 | Vonjo |
| Dova Pharmaceuticals | $12.68 | 2020 | |
| Advanced Accelerator Applications | $12.22 | 2020 |
Drugs and devices associated with these payments
Kisqali $1,782Keytruda $585Enhertu $438Calquence $344Fotivda $344Erleada $308Ojjaara $278Venclexta $266Rybrevant $239Jakafi $238Reblozyl $225Lenvima $211Akeega $195Lynparza $194Jaypirca $183Verzenio $183Polivy $183Adcetris $176Sarclisa $175Padcev $173Brukinsa $172Braftovi $165Mektovi $165Opdivo $164Zepzelca $164Orgovyx $163Libtayo $162Besremi $156Talvey $152Balversa $151Tukysa $150Scemblix $148Opdualag $146Precisetumor $137Elrexfio $135Vonjo $131Fabhalta $130Orserdu $117Xpovio $111Fruzaqla $110Tecentriq $110Nubeqa $106Doptelet $106Ibrance $98.37Imfinzi $97.93Zynlonta $96.14Rezlidhia $93.95Tavalisse $93.95Monoferric $91.44Tecvayli $91.02Pluvicto $89.03Rytelo $88.34Welireg $88.19Tivdak $85.67Xalkori $85.43Lorbrena $85.43Ultomiris $85.24Yescarta $82.77Alunbrig $81.77Rolvedon $79.48Zoladex $76.35Lunsumio $72.28Iclusig $71.72Monjuvi $70.81Onivyde $70.37Neulasta $70.12Avastin $70.12Neupogen $70.12Trodelvy $67.51Datroway $67.27Darzalex $64.33Keytruda Qlex $63.89Retevmo $63.32Imbruvica $61.44Tecentriq Hybreza $61.10Tibsovo $60.06Kimmtrak $58.67Danziten $58.40Inqovi $56.87Lonsurf $56.87Xtandi $56.62Talzenna $56.62Niktimvo $56.23Cablivi $54.31Zynyz $53.87Foundationone Cdx $53.83Vitrakvi $53.58Stivarga $53.58Carvykti $53.31Pomalyst $52.95Xt Cdx $52.28Inlyta $50.63Ogsiveo $49.69Qinlock $48.83Sir-Spheres Microspheres $45.37Accrufer $44.79Tasigna $43.26Columvi $42.15Shingrix $41.95Wayrilz $40.51
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.